NCT07422896 (Bvax) is a Phase 1 clinical trial of B-cell vaccination in Glioblastoma, sponsored by Catalina Lee Chang.

Who is sponsoring NCT07422896?

NCT07422896 is sponsored by Catalina Lee Chang.

What drugs are being tested in NCT07422896?

Interventions in NCT07422896: B-cell vaccination.

What condition does NCT07422896 study?

NCT07422896 studies Glioblastoma.

Is NCT07422896 still recruiting?

NCT07422896 is currently not yet recruiting. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT07422896: Bvax

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

Not yet recruiting Phase 1 Last updated 20 February 2026

What this trial tests

Phase 1 trial testing B-cell vaccination in Glioblastoma in 25 participants. Not yet recruiting.

Timeline

1 June 2026

Primary endpoint
1 June 2028

1 June 2030

Quick facts

Lead sponsor	Catalina Lee Chang
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 June 2026
Primary completion	1 June 2028
Estimated completion	1 June 2030
Sites	1 location across United States

Drugs / interventions tested

B-cell vaccination — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Catalina Lee Chang — full company profile →

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this phase I first-in-human trial are to evaluate safety, feasibility, and preliminary efficacy of an individualized Bvax vaccine in addition to standard of care chemoradiation in patients with newly diagnosed glioblastoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07422896 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catalina Lee Chang
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07422896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing